Abstracts tagged "radiography and rheumatoid arthritis (RA)"

Abstract Number: 1457 • 2013 ACR/ARHP Annual Meeting
Inhibitory Effect Of Abatacept On Joint Damage In Rheumatoid Arthritis Patients With Or Without Concomitant Methotrexate: A Retrospective Multicenter Analysis Of 12 Months Of Abatacept Treatment In Routine Clinical Practice
Isao Matsushita¹, Hiraku Motomura¹, Eiko Seki¹ and Tomoatsu Kimura², ¹Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan, ²Department of rthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan
Background/Purpose: Abatacept is approved for use with or without methotrexate (MTX). The purpose of this study was to clarify the inhibitory effect of abatacept on…
Abstract Number: 1464 • 2013 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcomes With Etanercept and Etanercept and Methotrexate In Patients With Rheumatoid Arthritis: Two-Year Results From The Canadian Methotrexate and Etanercept Outcome Study (CAMEO)
Boulos Haraoui¹, J. Carter Thorne², Edward C. Keystone³, Melanie Poulin-Costello⁴, Eric Trottier⁵, Andrew Vieira⁶ and Janet E. Pope⁷, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Medical Communications, Amgen Canada, Mississauga, ON, Canada, ⁶Amgen Canada Inc., Mississauga, ON, Canada, ⁷St Joseph Health Care, London, ON, Canada
Background/Purpose: Data from the CAMEO study demonstrated that patients with rheumatoid arthritis (RA) who achieved low disease activity (LDA) after 6 months of combination therapy…
Abstract Number: 1304 • 2013 ACR/ARHP Annual Meeting
Anti-Carbamylated Antibody Positivity Is Associated With More Severe Radiological Progression In Patients With Recent Onset ACPA Negative Rheumatoid Arthritis: Results From The Norfolk Arthritis Register (NOAR)
Jenny H. Humphreys¹, Suzanne M. Verstappen¹, Kimme L. Hyrich², Tarnya Marshall³, Anne Barton^4,5, René E.M. Toes⁶, Leendert A. Trouw⁶ and Deborah P. Symmons^4,7, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁵NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Autoantibodies against carbamylated proteins (anti-CarP) have been associated with more severe radiological damage in patients with rheumatoid arthritis (RA), including in a small subgroup…
Abstract Number: 1305 • 2013 ACR/ARHP Annual Meeting
Clinical Joint Involvement Is Decisive For Radiographic Progression
Miriam Gärtner¹, Farideh Alasti², Gabriela Supp¹, Josef S. Smolen³ and Daniel Aletaha¹, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Today’s therapeutic targets in rheumatoid arthritis (RA) are remission or low disease activity, but it was shown that joint damage may continue to progress…
Abstract Number: 1310 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The Japanese Patients With Rheumatoid Arthritis (RA) Of Rapid Radiographic Progression (RRP) Treated With Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) In Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (an interim report of Apple Survey)
Akitomo Okada¹, Atsushi Kawakami², Takaaki Fukuda³, Toshihiko Hidaka⁴, Tomonori Ishii⁵, Yukitaka Ueki⁶, Takao Kodera⁷, Munetoshi Nakashima¹, Yuichi Takahashi⁸, Seiyo Honda⁹, Yoshiro Horai², Tomohiro Koga¹⁰, Mami Tamai¹¹, Kiyoshi Aoyagi¹², Ryu Watanabe⁵, Hiroshi Okuno¹³ and Katsumi Eguchi¹⁴, ¹Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan, ⁴Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, ⁵Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ⁶Sasebo Chuo Hospital, Sasebo, Japan, ⁷Tohoku Kosei Nenkin Hospital, Sendai, Japan, ⁸Yu Family Clinic, Sendai, Japan, ⁹Kurume University School of Medicene, Kurume, Japan, ¹⁰Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹¹Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, ¹²Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹³Tohoku University Hospital, Sendai, Japan, ¹⁴Sasebo City General Hospital, Sasebo, Nagasaki, Japan
Background/Purpose: Disease modifying anti-rheumatic drugs (DMARDs) are known to inhibit radiographic progression in patients with rheumatoid arthritis (RA). However, there has been few epidemiological report…
Abstract Number: 812 • 2013 ACR/ARHP Annual Meeting
Alveolar Bone Loss Is Associated With Disease Activity and ACPA Expression In Rheumatoid Arthritis
Ted R. Mikuls¹, Jeffrey Payne², Fang Yu³, Geoffrey M. Thiele⁴, Shawneen Gonzalez², Jeffrey Markt⁵, Jeremy Sokolove⁶, William H. Robinson⁷, Richard J. Reynolds⁸, Grant W. Cannon⁹, David McGowan¹⁰, Gail S. Kerr¹¹, Robert Redman¹², Andreas M. Reimold¹³, Garth Griffiths¹⁴, Mark Beatty², Marian Schmid², Paul Johnson², Debra Bergman¹⁵, Bartlett C. Hamilton III¹⁶, Alan R. Erickson¹ and James R. O'Dell¹⁷, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴Int Med/Sec of Rheum/Immun, Univ of Nebraska Med Ctr, Omaha, NE, ⁵Otol-Head and Neck Surgery, University of Nebraska Medical Center, Omaha, NE, ⁶Stanford University, Palo Alto, CA, ⁷Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁸Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ¹⁰Dentistry, George E. Wahlen VA Medical Center, Salt Lake City, UT, ¹¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ¹²Dentistry, Washington DC VA, Georgetown and Howard University, Washington, DC, ¹³Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ¹⁴Dentistry, Dallas VA and University of Texas Southwestern, Dallas, TX, ¹⁵Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ¹⁶University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, NE, ¹⁷Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Periodontitis (PD) has been implicated in rheumatoid arthritis (RA) pathogenesis including the expression of anti-citrullinated protein antibody (ACPA). ACPA, in turn, have been shown…
Abstract Number: 350 • 2013 ACR/ARHP Annual Meeting
Cortical Bone Density As Measured By Digital X-Ray Radiogrammetry Correlates with Radiographic Joint Damage In The Hands Within 1 Year In Psoriatic Arthritis
Agnes Szentpetery¹, Muhammad Haroon², Phil Gallagher³, Eric J. Heffernan⁴ and Oliver FitzGerald², ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ³Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴Radiology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Structural destruction in peripheral joints may occur over time in both PsA and RA. We previously reported that 47% of early PsA patients treated…
Abstract Number: 812 • 2012 ACR/ARHP Annual Meeting
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase 3 Trial
Michael Weinblatt¹, Clifton O. Bingham III², Alan Mendelsohn³, Lenore Noonan⁴, Shihong Sheng⁵, Lilianne Kim⁶, Kim Hung⁶, Jiandong Lu⁶, Daniel Baker⁶ and Rene Westhovens⁷, ¹Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ²Department of Medicine, Johns Hopkins University, Baltimore, MD, ³Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁴Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁵Biostatistics, Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase…
Abstract Number: 766 • 2012 ACR/ARHP Annual Meeting
Anemia May Provide Clinically Relevant Information Beyond Conventional Disease Activity Assessment to Predict Radiographic Damage Progression in Rheumatoid Arthritis
Burkhard Moller¹, Frauke Förger², Peter M. Villiger³ and Axel Finckh⁴, ¹Rheumatology, Inselspital University Hospital, Bern, Switzerland, ²Rheumatology, Clinical Immunology and Allergology, Inselspital University Hospital of Bern, Bern, Switzerland, ³Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland, ⁴Rheumatology, Geneva University Hospitals, Geneva 14, Switzerland
Anemia may provide clinically relevant information beyond conventional disease activity assessment to predict radiographic damage progression in Rheumatoid ArthritisBurkhard Möller, Frauke Förger, Peter M. Villiger,…
Abstract Number: 2142 • 2012 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging-Proven Osteitis At Baseline Predicts the Early Rheumatoid Arthritis Patients Who Will Develop Rapid Radiographic Progression: MRI Is Beneficial to Find the Window of Opportunity in Early RA
Mami Tamai¹, Yoshikazu Nakashima², Takahisa Suzuki³, Yoshiro Horai², Akitomo Okada⁴, Junko Kita⁴, Shin-ya Kawashiri², Naoki Iwamoto⁴, Kunihiro Ichinose⁵, Kazuhiko Arima⁴, Hideki Nakamura¹, Tomoki Origuchi⁶, Masataka Uetani⁷, Kiyoshi Aoyagi⁸, Katsumi Eguchi⁹ and Atsushi Kawakami², ¹Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Radiology and Radiation Research, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁸Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁹Sasebo City General Hospital, Sasebo, Nagasaki, Japan
Background/Purpose: Window of opportunity exists in the earlier phase of rheumatoid arthritis (RA), thus, early recognition of the RA patients who will develop rapid radiographic…
Abstract Number: 770 • 2012 ACR/ARHP Annual Meeting
Is Late Onset Rheumatoid Arthritis (LORA) Really a Distinct Entity of RA? Results From the Swiss Observational Cohort
Ruediger Mueller¹, Toni Kaegi¹, Axel Finckh² and Johannes von Kempis¹, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Rheumatology, Geneva University Hospitals, Geneva 14, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) is generally described as a disease with two peaks of onset, either late (late onset RA, LORA) or early (young onset…
Abstract Number: 2133 • 2012 ACR/ARHP Annual Meeting
Relationship Between Clinical Response and Radiographic Outcomes in Patients with Moderate Rheumatoid Arthritis
Josef S. Smolen¹, Ronald F. van Vollenhoven², Andrew S. Koenig³, Ronald Pedersen³, Annette Szumski⁴ and Eustratios Bananis⁴, ¹Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, ³Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: Clinical evidence has established the importance of early, intensive treatment of rheumatoid arthritis (RA) to decrease disease activity and prevent joint damage.1 The objective…
Abstract Number: 403 • 2012 ACR/ARHP Annual Meeting
The Impact of Reaching Low Disease Activity in the First Year On Future Disability and Damage in Patients with Early Rheumatoid Arthritis
Pooneh Akhavan¹, George A. Tomlinson², Paul R. Fortin³ and Claire Bombardier¹, ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²Dept of Medicine/Rheumatology, Toronto General Hospital, Toronto, ON, Canada, ³Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada
Background/Purpose: Remission has been proposed as the goal of treatment in patients with early rheumatoid arthritis (RA) by current clinical practice guidelines. Remission is ideal…
Abstract Number: 2136 • 2012 ACR/ARHP Annual Meeting
Alcohol Use and Radiographic Disease Progression in African Americans with Recent Onset Rheumatoid Arthritis
Marshall Davis¹, Kaleb Michaud¹, Harlan Sayles¹, Doyt L. Conn², Larry W. Moreland³, S. Louis Bridges Jr.⁴ and Ted R. Mikuls¹, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, Emory Univ School of Medicine, Atlanta, GA, ³Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Previous studies have shown that alcoholic beverage consumption can modify levels of circulating inflammatory cytokines and alter expression of innate immune system receptors. Recognizing…
Abstract Number: 370 • 2012 ACR/ARHP Annual Meeting
Characteristic of the Japanese Patients with Rheumatoid Arthritis (RA) of Rapid Radiographic Progression (RRP) Treated with Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (the 1st report of Apple Survey)
Akitomo Okada¹, Atsushi Kawakami², Takaaki Fukuda³, Toshihiko Hidaka⁴, Tomonori Ishii⁵, Yukitaka Ueki⁶, Takao Kodera⁷, Munetoshi Nakashima⁸, Yuichi Takahashi⁹, Seiyo Honda¹⁰, Yoshiro Horai², Tomohiro Koga¹, Ryu Watanabe¹¹, Hiroshi Okuno¹² and Katsumi Eguchi¹³, ¹Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan, ⁴Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, ⁵Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ⁶Sasebo Chuo Hospital, Sasebo, Japan, ⁷Tohoku Kosei Nenkin Hospital, Sendai, Japan, ⁸Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁹Yu Family Clinic, Sendai, Japan, ¹⁰Kurume University School of Medicene, Kurume, Japan, ¹¹Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, ¹²Tohoku University Hospital, Sendai, Japan, ¹³Sasebo City General Hospital, Sasebo, Nagasaki, Japan
Background/Purpose: There has been few epidemiological report of longitudinal radiographic progression in rheumatoid arthritis (RA) patients captured in daily practice. In 20 related-centers of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].